Skip to content

Asset turnover at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
0.5×0.0×
Amgen logo
AmgenAMGN
0.4×0.0×
Tango Therapeutics logo
Tango TherapeuticsTNGX
0.2×0.0×
Arcus Biosciences logo
Arcus BiosciencesRCUS
0.2×+0.1×
Immunome logo
ImmunomeIMNM
0.0×
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
0.0×

Other financials

Income statement

See full
Revenue$6.6M
Operating income-$108.5M-28.6%
Net income-$98.5M-36.5%
EPS (diluted)-$1.11-35.4%

Balance sheet

See full
Cash & equivalents$157.5M+21.2%
Total debt$28.6M+10.1%
Total equity$937.3M-8.5%
Total assets$1.0B-6.4%

Cash flow

See full
Operating cash flow-$75.2M-24.6%
CapEx$967.0K-27.3%
Free cash flow-$76.1M-23.5%

Valuation

See full
Market cap$3.36B+104%
Enterprise value$3.23B+110%
P/S14.5×+9.9×

Profitability

See full
Operating margin-4,671.1%-5,434pp
Net margin-3,921.1%-4,562pp
FCF margin-3,592%-4,290pp

Returns & leverage

See full
Return on equity-14.3%-5.0pp
Debt / equity0.0×
Current ratio10.7×-3.2×

Where this comes from

Calculated from IDEAYA Biosciences, Inc.’s reported figures.

Based on trailing twelve months.

The official record: IDEAYA Biosciences, Inc.’s 10-K, filed February 17, 2026, on SEC EDGAR. View the filing →

Ask your AI about IDEAYA Biosciences, Inc.'s asset turnover.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is IDEAYA Biosciences, Inc.'s asset turnover?
IDEAYA Biosciences, Inc. (IDYA) reported asset turnover of 0× in Q4 2024.
How has IDEAYA Biosciences, Inc.'s asset turnover changed year-over-year?
IDEAYA Biosciences, Inc.'s asset turnover decreased by 82.5% year-over-year, from 0× to 0×.
What is the long-term trend for IDEAYA Biosciences, Inc.'s asset turnover?
Over 3 years (2021 to 2024), IDEAYA Biosciences, Inc.'s asset turnover has grown at a -54.2% compound annual growth rate (CAGR), from 0.1× to 0×.
What does asset turnover mean?
Trailing-twelve-month revenue divided by average total assets. Measures how many dollars of sales each dollar of assets generates — the efficiency leg of the DuPont decomposition of ROE.